The Evaluation of Glycyrrhizic Acid's Pesticide Effect in Treating Liver Damage (Retrospective Study）

Liver Damage Clinical Trial

Official title:

The Evaluation of Glycyrrhizic Acid's Pesticide Effect in Treating Liver Damage (Retrospective Study）

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02329314
• Other study ID #: 2014-365-61-01
• Status: Recruiting
• Phase: N/A
• First received: December 26, 2014
• Last updated: December 30, 2014
• Start date: November 2014
• Est. completion date: June 2016

Study information

• Verified date: December 2014
• Source: ShuGuang Hospital
• Contact: Wu Chao, postgraduate
• Phone: 15221095202
• Email: 15221095202[@]163.com
• Is FDA regulated: No
• Health authority: China: Ethics Committee
• Study type: Observational

Clinical Trial Summary

Collect the details about hepatic dysfunctional patients induced by various etiology who have a usage of Glycyrrhizic Acid, then arrange and analyse the data to evaluate the clinical curative effect of glycyrrhizic acid.

Description:

This experiment will screen and collect qualified cases from medical records in Shuguang Hospital.to collect the patients with liver injury in clinic, including (1) conforms to ALT>1.5 times the normal value or >70 IU/L, age 18 to 70 years of age, sex is not limited; (2) patients with viral hepatitis or cirrhosis of the liver, or autoimmune liver disease, or schistosomiasis, or drug-induced liver damage, or for other reasons clear or unclear leading to abnormal liver function ; (3) except for tumor patients. The index of liver function such as ALT, AST, Alb, et al are detected respectively before and after preventive treatment of the glycyrrhizic acid for liver injury ,and through the synthesizing of the single sample difference t test and clinical practice to analyze the clinical efficacy of glycyrrhizin intervention treatment of hepatic injury

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: June 2016
• Est. primary completion date: June 2016
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. conforms to ALT>1.5 times the normal value or >70IU/L, age 18 to 70 years of age, sex is not limited;

2. patients with viral hepatitis or cirrhosis of the liver, or autoimmune liver disease, or schistosomiasis, or drug-induced liver damage, or for other reasons clear or unclear leading to abnormal liver function ;

Exclusion Criteria:

1. patients with tumor;

2. pregnant or lactating women, and pregnancy may not take effective contraceptive measures;

3. complicated with serious heart, lung, gallbladder, kidney, endocrine, hematopoietic system and mental disease;

4. the researchers think that should not be selected for this test.

Study Design

Observational Model: Case-Only, Time Perspective: Retrospective

Related Conditions & MeSH terms

• Liver Damage

Locations

Country	Name	City	State
China	Shuguang Hospital	Shanghai	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
ShuGuang Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Biochemical indexes measured before and after the interference	to measure biochemical indexes such as ALT, AST, ALB, TBiL, et al before and after the interference with Glycyrrhizic Acid	1-4 weeks	No